FEI CHU¹, KAI TONG¹, XIANG GU¹, MEI BAO¹, YANFEN CHEN¹, BIN WANG², YANHUA SHAO¹, LING WEI^1,*

Oncology Research, Vol.32, No.10, pp. 1661-1671, 2024, DOI:10.32604/or.2024.048287 - 18 September 2024

Abstract Glutamine is one of the most abundant non-essential amino acids in human plasma and plays a crucial role in many biological processes of the human body. Tumor cells take up a large amount of glutamine to meet their rapid proliferation requirements, which is supported by the upregulation of glutamine transporters. Targeted inhibition of glutamine transporters effectively inhibits cell growth and proliferation in tumors. Among all cancers, digestive system malignant tumors (DSMTs) have the highest incidence and mortality rates, and the current therapeutic strategies for DSMTs are mainly surgical resection and chemotherapy. Due to the relatively More > Graphic Abstract

STEPHEN E. LANGABEER^*

Oncology Research, Vol.32, No.9, pp. 1423-1427, 2024, DOI:10.32604/or.2024.051218 - 23 August 2024

Abstract Hairy cell leukemia (HCL) is an uncommon mature B-cell malignancy characterized by a typical morphology, immunophenotype, and clinical profile. The vast majority of HCL patients harbor the canonical BRAF V600E mutation which has become a rationalized target of the subsequently deregulated RAS-RAF-MEK-MAPK signaling pathway in HCL patients who have relapsed or who are refractory to front-line therapy. However, several HCL patients with a classical phenotype display non-canonical BRAF mutations or rearrangements. These include sequence variants within alternative exons and an oncogenic fusion with the IGH gene. Care must be taken in the molecular diagnostic work-up of patients More >

QIUQIANG CHEN^1,*, XUEJUN GUO², WENXUE MA^3,*

Oncology Research, Vol.32, No.1, pp. 49-60, 2024, DOI:10.32604/or.2023.042383 - 15 November 2023

Abstract Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer, with the tumor microenvironment (TME) playing a pivotal role in modulating the immune response. CD47, a cell surface protein, has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However, the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain incompletely understood. This comprehensive review aims to provide an overview of CD47’s multifaced role in TME regulation and immune evasion, elucidating its impact on various types of immunotherapy… More > Graphic Abstract

ELYN AMIELA SALLEH¹, YEONG YEH LEE², ANDEE DZULKARNAEN ZAKARIA³, NUR ASYILLA CHE JALIL⁴, MARAHAINI MUSA^1,*

BIOCELL, Vol.47, No.10, pp. 2233-2244, 2023, DOI:10.32604/biocell.2023.030541 - 08 November 2023

Abstract Colorectal cancer (CRC) is a major global health concern. Accumulation of cancer-associated fibroblasts (CAFs) in CRC is associated with poor prognosis and disease recurrence. CAFs are the main cellular component of the tumor microenvironment. CAF-tumor cell interplay, which is facilitated by various secretomes, drives colorectal carcinogenesis. The complexity of CAF populations contributes to the heterogeneity of CRC and influences patient survival and treatment response. Due to their significant roles in colorectal carcinogenesis, different clinical applications utilizing or targeting CAFs have been suggested. Circulating CAFs (cCAFs) which can be detected in blood samples, have been proposed… More > Graphic Abstract

DONGYANG WANG, YI CHEN, JING HUANG, YOU ZHANG, CHONGKUI SUN, YINGQIANG SHEN^*

BIOCELL, Vol.47, No.2, pp. 329-338, 2023, DOI:10.32604/biocell.2023.023489 - 18 November 2022

Abstract Glucocorticoids (GC) are widely used to counter the adverse events during cancer therapy; nonetheless, previous studies pointed out that GC may reduce the efficacy of chemotherapy on cancer cells, especially in epidermal growth factor receptor (EGFR)-targeted therapy of head and neck squamous cell carcinoma (HNSCC) remaining to be elucidated. The primary aim of the present study was to probe into the GC-induced resistance of EGFR-targeted drug afatinib and the underlying mechanism. HNSCC cell lines (HSC-3, SCC-25, SCC-9, and H-400) and the human oral keratinocyte (HOK) cell lines were assessed for GC receptor (GR) expression. The… More >

YUNG-SUNG YEH^1,2,3, HSIANG-LIN TSAI^4,5, YEN-CHENG CHEN^4,6, WEI-CHIH SU^4,6, PO-JUNG CHEN^4,6, TSUNG-KUN CHANG^4,6,7, CHING-CHUN LI⁴, CHING-WEN HUANG^4,5, JAW-YUAN WANG^{4,5,6,8,9,10,*}

Oncology Research, Vol.30, No.2, pp. 65-76, 2022, DOI:10.32604/or.2022.026659 - 05 January 2023

Abstract The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients with mCRC for metastasectomy remain undefined. This retrospective study compared the efficacy, safety, and survival of cycles of neoadjuvant chemotherapy/targeted therapy for such patients. Sixty-four patients with mCRC who received neoadjuvant chemotherapy/targeted therapy following metastasectomy were enrolled between January 2018 and April 2022. Twenty-eight patients received 6 cycles of chemotherapy/targeted therapy, whereas 36 patients received ≥7 cycles (median, 13; range, 7–20). Clinical outcomes, including response,… More >

Jiajian Shi¹, Yuchen Chen^1,*, Chentai Peng¹, Linwu Kuang², Zitong Zhang¹, Yangkai Li^2,*, Kun Huang¹

Oncologie, Vol.24, No.4, pp. 613-648, 2022, DOI:10.32604/oncologie.2022.027545 - 31 December 2022

Abstract The incidence and mortality of lung cancer rank top three of all cancers worldwide. Accounting for 85% of the total number of lung cancer, non-small cell lung cancer (NSCLC) is an important factor endangering human health. Recently, targeted therapies against driver mutations and epigenetic alterations have made encouraging advances that benefit NSCLC patients. Druggable driver mutations, which mainly occur in EGFR, KRAS, MET, HER2, ALK, ROS1, RET and BRAF, have been identified in more than a quarter of NSCLC patients. A series of highly selective mutant targeting inhibitors, such as EGFR tyrosine kinase inhibitors and KRAS inhibitors, have been… More >

Mengjie Li^1,#, Jun Wei^2,#, Guihua Xu^3,#, Ying Liu^3,*, Jian Zhu^3,*

Oncologie, Vol.24, No.2, pp. 349-356, 2022, DOI:10.32604/oncologie.2022.022436 - 29 June 2022

Abstract Gastrointestinal stromal tumors (GISTs) are rare neoplasms arising from mesenchymal cells of the digestive tract and abdomen. Only a few isolated cases of giant esophageal GISTs (greater than 5 cm in size) have been reported with clinical features and surgical methods. Radical esophagectomy with negative margins, followed by gastric tube reconstruction, is recommended for giant esophageal GISTs. However, patients undergoing this type of surgery experienced a sharp decrease in food intake (due to the removal of most of the stomach) and were prone to eating regurgitation, resulting in poor quality of life. We describe the… More >

RUI ZHOU^#, JIANYANG XU^#, LINGWEI WANG^*, JIANXIN LI^*

Oncology Research, Vol.29, No.6, pp. 411-423, 2021, DOI:10.32604/or.2022.026236 - 10 November 2022

Abstract Long noncoding RNAs (lncRNAs) act as key regulators controlling complex cellular behaviors in nonsmall cell lung cancer (NSCLC). We investigated the expression of lncRNA PRRT3 antisense RNA 1 (PRRT3-AS1) in paired samples of NSCLC and adjacent normal tissues from a patient cohort in our hospital using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) and found that it was significantly higher in NSCLC tissue than in normal tissue, consistent with The Cancer Genome Atlas database. Furthermore, functional investigation revealed that lncRNA PRRT3-AS1 depletion inhibited NSCLC-cell proliferation, colony formation, invasion, and migration, whereas its overexpression exerted… More >

MARGARET SIMONIAN^*

BIOCELL, Vol.45, No.6, pp. 1459-1463, 2021, DOI:10.32604/biocell.2021.017369 - 01 September 2021

Abstract Pediatric central nervous system tumors are the most common tumors in children, it constitute 15%–20% of all malignancies in children and are the leading cause of cancer related deaths in children. Proteogenomics is an emerging field of biological research that utilizes a combination of proteomics, genomics, and transcriptomics to aid in the discovery and identification of biomarkers for diagnosis and therapeutic purposes. Integrative proteogenomics analysis of pediatric tumors identified underlying biological processes and potential treatments as well as the functional effects of somatic mutations and copy number variation driving tumorigenesis. More >